Droste-Med, Drostanolone Propionate, 150 mg/ml, 10 ml

Drostanolone Propionate 150 mg/ml by Bioniche Pharma is a fast-acting parenteral anabolic agent derived from dihydrotestosterone (DHT). Engineered by Bioniche Pharma with a short propionate ester chain to ensure a swift onset of action, Bioniche Pharma Drostanolone Propionate provides selective anabolic support without undergoing aromatic conversion to estrogen, serving as an efficient compound for preserving lean tissue and encouraging cellular recovery.

CLINICAL PHARMACOLOGY & MECHANISM OF ACTION

Drostanolone Propionate by Bioniche Pharma functions by interacting directly with intracellular nuclear androgen receptors, driving anabolic pathways, boosting cellular nitrogen conservation, and accelerating protein translation. Being a non-aromatizable DHT derivative, Bioniche Pharma Drostanolone Propionate cannot convert into estrogen, thereby preventing risks of gynecomastia and subcutaneous water retention while exhibiting inherent anti-estrogenic properties.

INDICATIONS & CLINICAL USE

• Palliative care for advanced, hormone-responsive breast cancer in postmenopausal female patients using Bioniche Pharma treatment protocols.
• Therapeutic support to foster tissue repair and functional recovery following major surgical procedures or severe physical trauma.
• Adjunctive management for specific growth delay conditions under specialized endocrinological oversight.

CONTRAINDICATIONS

• Male patients presenting with confirmed or suspected prostate carcinoma or male breast cancer.
• Female breast carcinoma complicated by severe hypercalcemia (elevated blood calcium levels).
• Severe renal failure or advanced primary hepatic pathology.
• Pregnancy and nursing due to severe risks of fetal toxicity, structural malformation, and female virilization.
• Known hypersensitivity or allergic response to Drostanolone Propionate, carrier oils, or inactive compounding excipients in Bioniche Pharma preparations.

PRECAUTIONS & METABOLIC MONITORS

• Glycemic Monitoring: Anabolic-androgenic agents can alter peripheral glucose clearance and insulin sensitivity. Diabetic patients undergoing Bioniche Pharma Drostanolone Propionate therapy should perform frequent blood glucose testing, as anti-diabetic medication dosages may require adjustment.
• Pediatric Caution: Heightened clinical vigilance is required in young patients receiving Bioniche Pharma formulations due to increased sensitivity to androgenic stimulation and the risk of premature epiphyseal plate fusion.
• Lipid & Hepatic Surveillance: Periodic evaluation of serum lipid fractions (HDL and LDL cholesterol) and baseline liver function parameters is recommended throughout Bioniche Pharma treatment.

ADVERSE REACTIONS

• Dermatological & Androgenic: Heightened sebum production, acne vulgaris, accelerated facial or body hair growth (hirsutism), and aggravation of androgenetic alopecia (male pattern baldness) in predisposed individuals treated with Bioniche Pharma Drostanolone Propionate.
• Endocrine & Systemic: Reversible suppression of pituitary gonadotropin release and potential virilizing features in female patients following extended exposure to Bioniche Pharma formulations.

DOSAGE & ADMINISTRATION

Drostanolone Propionate by Bioniche Pharma is formulated strictly for deep intramuscular injection. Due to the fast clearance rates of the propionate ester, administration is typically scheduled 2 to 3 times per week:

• Therapeutic Schedule: Standard clinical dosages for Bioniche Pharma Drostanolone Propionate generally range from 150 mg to 450 mg weekly, customized and monitored under direct medical supervision based on therapeutic goals and patient tolerance.

STORAGE & HANDLING

Store Bioniche Pharma Drostanolone Propionate in a dry, cool environment protected from direct sunlight exposure and elevated temperatures. Do not refrigerate or freeze. Store securely out of the reach and sight of children.